---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-033856"
form_type: "8-K"
ticker: "BBIO"
cik: "0001743881"
company_name: "BridgeBio Pharma, Inc."
filed_at: "2024-07-23T23:59:59+00:00"
generated_at: "2026-05-31T18:08:52.830234+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# BridgeBio appoints Thomas Trimarchi as President and COO; Neil Kumar remains CEO

## Summary
- Thomas Trimarchi appointed President and COO effective July 23, 2024; Neil Kumar steps down as President but stays CEO and director.
- Trimarchi previously served as Chief Product Officer since 2018; also board member of affiliate ML Bio Solutions (BBP-418 for LGMD2I/R9).
- Newly created role to drive operational excellence, strategic planning, and centralize late-stage pipeline operations.
- Trimarchi holds a Ph.D. in Molecular Oncology and Immunology from NYU; prior roles at Regeneron and Goldman Sachs.

## SEC filing metadata
- accession: 0001140361-24-033856
- form_type: 8-K
- ticker: BBIO
- cik: 0001743881
- company_name: BridgeBio Pharma, Inc.
- filed_at: 2024-07-23T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1743881/000114036124033856/0001140361-24-033856-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1743881/000114036124033856/ef20032871_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-033856
- JSON: https://secwatch.observer/filing/0001140361-24-033856.json
- Plain text: https://secwatch.observer/filing/0001140361-24-033856.txt

## Key facts
- Executive change
  Neil Kumar changed role as President at BridgeBio Pharma, Inc..
  - Action: stepped down
  - Role: President
  source text: Neil Kumar, Ph.D. stepped down as President
  evidence_url: https://www.sec.gov/Archives/edgar/data/1743881/000114036124033856/0001140361-24-033856-index.htm
- Executive change
  Thomas Trimarchi was appointed as President and Chief Operating Officer at BridgeBio Pharma, Inc..
  - Action: appointed
  - Role: President and Chief Operating Officer
  source text: Thomas Trimarchi was appointed as the Company’s President and Chief Operating Officer
  evidence_url: https://www.sec.gov/Archives/edgar/data/1743881/000114036124033856/0001140361-24-033856-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.